Intermittent Fasting with GLP-1 for Reduced Dyslipidemia: A Promising Strategy for Improved Metabolic Health
What is Intermittent Fasting with GLP-1?
Intermittent fasting (IF) and glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as promising strategies for reducing dyslipidemia, a major risk factor for cardiovascular disease. GLP-1, a gastrointestinal peptide, plays a crucial role in glucose metabolism, insulin sensitivity, and appetite regulation. When combined with IF, GLP-1 can amplify the benefits of both methods, leading to improved metabolic health and reduced lipids.Understanding GLP-1 and Intermittent Fasting
